S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:RUBY

Rubius Therapeutics Stock Forecast, Price & News

$12.56
+2.16 (+20.77 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.09
Now: $12.56
$15.18
50-Day Range
$8.02
MA: $11.48
$14.93
52-Week Range
$3.35
Now: $12.56
$15.99
Volume2.99 million shs
Average Volume761,768 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Rubius Therapeutics logo

Headlines

Is Rubius (RUBY) A Good Stock To Buy Now?
December 11, 2020 |  finance.yahoo.com
Rubius Therapeutics EPS beats by $0.03
August 10, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
CUSIPN/A
CIKN/A
Phone617-679-9600
Employees197
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.44 per share

Profitability

Net Income$-163,460,000.00

Miscellaneous

Market Cap$1.02 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

468th out of 1,972 stocks

Biological Products, Except Diagnostic Industry

65th out of 177 stocks

Analyst Opinion: 1.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$12.56
+2.16 (+20.77 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

Is Rubius Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Rubius Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RUBY, but not buy additional shares or sell existing shares.
View analyst ratings for Rubius Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Rubius Therapeutics?

Wall Street analysts have given Rubius Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rubius Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Rubius Therapeutics
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its quarterly earnings results on Tuesday, February, 23rd. The company reported ($0.50) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.53) by $0.03.
View Rubius Therapeutics' earnings history
.

How has Rubius Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RUBY shares have increased by 91.8% and is now trading at $12.56.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RUBY?

5 analysts have issued 1 year price targets for Rubius Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they expect Rubius Therapeutics' stock price to reach $13.25 in the next year. This suggests a possible upside of 5.5% from the stock's current price.
View analysts' price targets for Rubius Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein, Exec. Chairman (Age 59, Pay $495k)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 58, Pay $785.88k)
  • Ms. Maiken Keson-Brookes, Chief Legal Officer & Corp. Sec. (Age 48, Pay $190.17k)
  • Mr. Jose Carmona, CFO, Principal Accounting Officer & Treasurer (Age 49)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 52)
  • Mr. Spencer Fisk, Sr. VP & Chief Technical Operations Officer
  • Mr. Laurence A. Turka M.D., Chief Scientific Officer (Age 63)
  • Ms. Lori Melancon, VP of Corp. Communications & Investor Relations
  • Ms. Elhan Webb C.F.A., VP of Investor Relations
  • Mr. Theo Proukou, Sr. VP & Chief People Officer

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics CEO Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among Rubius Therapeutics' employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (5.82%), BlackRock Inc. (4.01%), JPMorgan Chase & Co. (3.20%), Federated Hermes Inc. (0.74%), Norges Bank (0.55%) and Northern Trust Corp (0.51%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen.
View institutional ownership trends for Rubius Therapeutics
.

Which institutional investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Tudor Investment Corp Et Al, Squarepoint Ops LLC, Russell Investments Group Ltd., Trexquant Investment LP, Jane Street Group LLC, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Rubius Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Rubius Therapeutics stock?

RUBY stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Baillie Gifford & Co., JPMorgan Chase & Co., HITE Hedge Asset Management LLC, Hsbc Holdings PLC, ExodusPoint Capital Management LP, SG Americas Securities LLC, and Centaurus Financial Inc.. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, and Pablo J Cagnoni.
View insider buying and selling activity for Rubius Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $12.56.

How much money does Rubius Therapeutics make?

Rubius Therapeutics has a market capitalization of $1.02 billion. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does Rubius Therapeutics have?

Rubius Therapeutics employs 197 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

Where are Rubius Therapeutics' headquarters?

Rubius Therapeutics is headquartered at 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.